Mark A. Murakami

Mark A. Murakami

Auto-generated profile, based on publicly available information

Mark A. Murakami

Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2025 in Blood
Verified
Journal Article
Closed access
MLMarlise R. Luskin
Marlise R. Luskin
MMMark A. Murakami
Mark A. Murakami
JKJulia Keating
Julia Keating
YFYael Flamand
Yael Flamand
EWEric S. Winer
Eric S. Winer
DDDaniel J. DeAngelo
Daniel J. DeAngelo
Dasatinib is an effective treatment for Philadelphia chromosome–positive (Ph+) acute leukemia, but some patients develop resistance. Combination treatment with dasatinib and asciminib, an allosteric inhibitor of BCR::ABL1, may deepen responses and prevent the emergence of dasatinib-resistant clones. In this phase 1 study (NCT03595017), 24 adults with Ph+ acute lymphoblastic leukemia (ALL; n = 22; p190, n = 16; p210, n = 6) and chronic myeloid leukemia in lymphoid blast crisis (n = 2) were treated with escalating daily doses of asciminib in combination with dasatinib 140 mg daily plus prednisone 60 mg/m2 daily to determine the maximum tolerated dose. After a 28-day induction, dasatinib and asciminib were continued indefinitely or until hematopoietic stem cell transplant. The median age was 64.5 years (range, 33-85; 50% aged ≥65 years). The recommended phase 2 dose of asciminib was 80 mg daily in combination with dasatinib and prednisone. The dose limiting toxicity at 160 mg daily was asymptomatic grade 3 pancreatic enzyme elevation without symptomatic pancreatitis. There were no vaso-occlusive events. Among patients with de novo ALL, the complete hematologic remission rates at days 28 and 84 were 84% and 100%, respectively. At day 84, 100% of patients achieved complete cytogenetic remission, 89% achieved measurable residual disease negativity (<0.01%) by multicolor flow cytometry, and 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively. Dual BCR::ABL1 inhibition with dasatinib and asciminib is safe with encouraging activity in patients with de novo Ph+ ALL. This trial was registered at www.clinicaltrials.gov as #NCT02081378.

20 May 2025 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
WWWeida Wu
Weida Wu
SISarah H. Ishamuddin
Sarah H. Ishamuddin
TQThomas W. Quinn
Thomas W. Quinn
SYSmitha Yerrum
Smitha Yerrum
YZYe Zhang
Ye Zhang
SMScott R. Manalis
Scott R. Manalis

18 April 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MMMark A. Murakami
Mark A. Murakami
LCLaura S Connelly-Smith
Laura S Connelly-Smith
TSThomas Spitzer
Thomas Spitzer
AKAdetola A Kassim
Adetola A Kassim
SPSam L. Penza
Sam L. Penza
HSHeather E. Stefanski
Heather E. Stefanski
Data on recent bone marrow harvest (BMH) collections from the NMDP has shown that bone marrow (BM) quality has decreased based on total nucleated cell count in the product. To ensure that quality BM products are available to all recipients, the NMDP Marrow Alliance was formed in April 2021 to increase the capability of BM collection centers to safely deliver high-quality products consistently and to identify and disseminate guidelines for performing BMH. This white paper describes the best practices for BMH as defined by the NMDP Marrow Alliance.

10 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PWPeter Winter
Peter Winter
MRMichelle L. Ramseier
Michelle L. Ramseier
ANAndrew W. Navia
Andrew W. Navia
SSSachit Saksena
Sachit Saksena
HSHaley Strouf
Haley Strouf
MMMark A. Murakami
Mark A. Murakami
SUMMARY: Efforts to cure BCR::ABL1 B cell acute lymphoblastic leukemia (Ph+ ALL) solely through inhibition of ABL1 kinase activity have thus far been insufficient despite the availability of tyrosine kinase inhibitors (TKIs) with broad activity against resistance mutants. The mechanisms that drive persistence within minimal residual disease (MRD) remain poorly understood and therefore untargeted. Utilizing 13 patient-derived xenograft (PDX) models and clinical trial specimens of Ph+ ALL, we examined how genetic and transcriptional features co-evolve to drive progression during prolonged TKI response. Our work reveals a landscape of cooperative mutational and transcriptional escape mechanisms that differ from those causing resistance to first generation TKIs. By analyzing MRD during remission, we show that the same resistance mutation can either increase or decrease cellular fitness depending on transcriptional state. We further demonstrate that directly targeting transcriptional state-associated vulnerabilities at MRD can overcome BCR::ABL1 independence, suggesting a new paradigm for rationally eradicating MRD prior to relapse. Finally, we illustrate how cell mass measurements of leukemia cells can be used to rapidly monitor dominant transcriptional features of Ph+ ALL to help rationally guide therapeutic selection from low-input samples. HIGHLIGHTS: Relapse after remission on TKI can harbor mutations in ABL1, RAS, or neither Mutations and development-like cell state dictate fitness in residual disease Co-targeting cell state and ABL1 markedly reduces MRD Biophysical measurements provide an integrative, rapid measurement of cell state

5 December 2025 in Science Advances
Verified
Journal Article
Open access
YZYe Zhang
Ye Zhang
LDLydie Debaize
Lydie Debaize
ALAdam Langenbucher
Adam Langenbucher
JWJenalyn Weekes
Jenalyn Weekes
IVIoulia Vogiatzi
Ioulia Vogiatzi
MMMark A. Murakami
Mark A. Murakami
Intratumor heterogeneity impacts disease progression and therapeutic resistance but remains poorly characterized by conventional histologic, immunophenotypic, and molecular approaches. Single-cell biophysical properties distinguish functional phenotypes complementary to these approaches, providing additional insight into cellular diversity. Here, we link both buoyant mass and stiffness to gene expression to identify clinically relevant phenotypes within primary mantle cell lymphoma (MCL) cells, using MCL as a model of biological and clinical diversity in human cancer. Linked measurements reveal that buoyant mass and stiffness characterize B cell development states from naïve to plasma cell and correlate with expression of oncogenic B cell receptor signaling genes such as BLK and CD79A . In addition, changes in cell buoyant mass within primary patient specimens ex vivo correlate with sensitivity to Bruton’s tyrosine kinase inhibitors in vivo in MCL and chronic lymphocytic leukemia, another B cell malignancy. These findings highlight the value of biophysical properties as biomarkers of response in pursuit of future precision therapeutic strategies.

27 May 2026 in Blood Advances
Verified
Journal Article
Open access
PDF file
RXRan Xu
Ran Xu
GWGongwei Wu
Gongwei Wu
SRSiobhan Rice
Siobhan Rice
MBMatthew Booker
Matthew Booker
JWJenalyn Celine Weekes
Jenalyn Celine Weekes
ALAndrew A Lane
Andrew A Lane
Many cancer therapies induce high response rates, with some resulting in undetectable disease as assessed using standard clinical assays. This is particularly true in leukemia and lymphoma, in which patients often achieve deep remission yet ultimately experience relapse. These outcomes highlight a critical need to better understand ultrarare persistent cells that survive therapy but remain inaccessible to current techniques. Here, we developed Live-cell Pick-Seq (LiP-Seq), an advanced platform leveraging multiplexed live-cell imaging to identify and retrieve individual target cells for downstream analysis. LiP-Seq enables high-resolution transcriptomic profiling of single, viable lymphoma cells present at frequencies as low as 10−6, providing a technological window into the biology of these elusive reservoirs. Applying this method to patients with mantle cell lymphoma after treatment with CD19 chimeric antigen receptor T-cell (CAR-T) therapy, we identified recurrent upregulation of the immune modulator IFITM2 in the persistent cell fraction. Functional validation demonstrated that IFITM2 overexpression conferred protection against CAR-T cytotoxicity in vitro, implicating it as a potential survival mechanism under therapeutic pressure. Our results provide, to our knowledge, the first transcriptomic characterization of viable, ultrarare persistent cells using LiP-Seq, establishing a new paradigm for identifying and targeting features that may enable treatment evasion.